{"id":"https://openalex.org/W2126906384","doi":"https://doi.org/10.2174/138920012800840464","title":"Sex Differences in the Clearance of CYP3A4 Substrates: Exploring Possible Reasons for the Substrate Dependency and Lack of Consensus","display_name":"Sex Differences in the Clearance of CYP3A4 Substrates: Exploring Possible Reasons for the Substrate Dependency and Lack of Consensus","alternate_titles":[],"publication_year":2012,"publication_date":"2012-06-01","ids":{"openalex":"https://openalex.org/W2126906384","doi":"https://doi.org/10.2174/138920012800840464","mag":"2126906384","pmid":"https://pubmed.ncbi.nlm.nih.gov/22452452"},"language":"en","primary_location":{"id":"doi:10.2174/138920012800840464","doi":"https://doi.org/10.2174/138920012800840464","is_oa":false,"landing_page_url":"https://doi.org/10.2174/138920012800840464","pdf_url":null,"source":{"id":"https://openalex.org/S195680726","display_name":"Current Drug Metabolism","issn_l":"1389-2002","issn":["1389-2002","1875-5453"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Drug Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2126906384"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002054470","display_name":"Manoranjenni Chetty","orcid":"https://orcid.org/0000-0001-8900-956X","observed_orcids":["https://orcid.org/0000-0001-8900-956X"]},"institutions":[{"id":"https://openalex.org/I4210161181","display_name":"Simcyp (United Kingdom)","ror":"https://ror.org/02j65kc59","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210161181"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Manoranjenni Chetty","raw_affiliation_strings":["Simcyp Limited, Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK. m.chetty@simcyp.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Simcyp Limited, Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK. m.chetty@simcyp.com","institution_ids":["https://openalex.org/I4210161181"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023758717","display_name":"Donald R. Mattison","orcid":"https://orcid.org/0000-0001-5623-0874","observed_orcids":["https://orcid.org/0000-0001-5623-0874"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald Mattison","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5051566641","display_name":"Amin Rostami\u2010Hodjegan","orcid":"https://orcid.org/0000-0003-3917-844X","observed_orcids":["https://orcid.org/0000-0003-3917-844X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amin Rostami-Hodjegan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.9722,"has_fulltext":false,"cited_by_count":44,"citation_normalized_percentile":{"value":0.94323097,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"13","issue":"6","first_page":"778","last_page":"786"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13252","display_name":"Sex and Gender in Healthcare","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sex-differences","display_name":"sex differences","score":0.8939999938011169},{"id":"https://openalex.org/keywords/cyp3a4-substrates","display_name":"CYP3A4 substrates","score":0.9739999771118164},{"id":"https://openalex.org/keywords/drug-clearance","display_name":"drug clearance","score":0.9610000252723694},{"id":"https://openalex.org/keywords/population-pharmacokinetic-model","display_name":"population pharmacokinetic model","score":0.7360000014305115},{"id":"https://openalex.org/keywords/statistical-power","display_name":"statistical power","score":0.9010000228881836},{"id":"https://openalex.org/keywords/in-vitro-in-vivo-extrapolation","display_name":"in vitro-in vivo extrapolation","score":0.7269999980926514},{"id":"https://openalex.org/keywords/midazolam","display_name":"midazolam","score":0.8259999752044678},{"id":"https://openalex.org/keywords/triazolam","display_name":"triazolam","score":0.9919999837875366},{"id":"https://openalex.org/keywords/alprazolam","display_name":"alprazolam","score":0.9990000128746033},{"id":"https://openalex.org/keywords/nifedipine","display_name":"nifedipine","score":1.0},{"id":"https://openalex.org/keywords/zolpidem","display_name":"zolpidem","score":1.0},{"id":"https://openalex.org/keywords/simcyp","display_name":"SimCYP","score":0.6119999885559082}],"concepts":[{"id":"https://openalex.org/C2777196872","wikidata":"https://www.wikidata.org/wiki/Q319877","display_name":"Alprazolam","level":3,"score":0.784356951713562},{"id":"https://openalex.org/C2779738154","wikidata":"https://www.wikidata.org/wiki/Q412143","display_name":"Triazolam","level":4,"score":0.7120239734649658},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6207345724105835},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6029868125915527},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.5588986277580261},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5155696868896484},{"id":"https://openalex.org/C2778000748","wikidata":"https://www.wikidata.org/wiki/Q423071","display_name":"Midazolam","level":3,"score":0.4942893981933594},{"id":"https://openalex.org/C3946865","wikidata":"https://www.wikidata.org/wiki/Q5014962","display_name":"CYP2C9","level":4,"score":0.45404258370399475},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.44956326484680176},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.448804646730423},{"id":"https://openalex.org/C33664856","wikidata":"https://www.wikidata.org/wiki/Q3271142","display_name":"CYP2D6","level":4,"score":0.4482375681400299},{"id":"https://openalex.org/C77350462","wikidata":"https://www.wikidata.org/wiki/Q1125472","display_name":"Confounding","level":2,"score":0.4479750692844391},{"id":"https://openalex.org/C2777123777","wikidata":"https://www.wikidata.org/wiki/Q218842","display_name":"Zolpidem","level":3,"score":0.42259469628334045},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.3351292014122009},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3248096704483032},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.27299898862838745},{"id":"https://openalex.org/C2778173252","wikidata":"https://www.wikidata.org/wiki/Q83871","display_name":"Benzodiazepine","level":3,"score":0.22483617067337036},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.14351993799209595},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.12750688195228577},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09778988361358643},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.08514580130577087},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08019664883613586},{"id":"https://openalex.org/C2781210498","wikidata":"https://www.wikidata.org/wiki/Q1869874","display_name":"Insomnia","level":2,"score":0.0},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.0},{"id":"https://openalex.org/C2776814716","wikidata":"https://www.wikidata.org/wiki/Q574801","display_name":"Sedation","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D003198","descriptor_name":"Computer Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009543","descriptor_name":"Nifedipine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D012727","descriptor_name":"Sex Characteristics","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.2174/138920012800840464","doi":"https://doi.org/10.2174/138920012800840464","is_oa":false,"landing_page_url":"https://doi.org/10.2174/138920012800840464","pdf_url":null,"source":{"id":"https://openalex.org/S195680726","display_name":"Current Drug Metabolism","issn_l":"1389-2002","issn":["1389-2002","1875-5453"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Drug Metabolism","raw_type":"journal-article"},{"id":"pmid:22452452","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22452452","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current drug metabolism","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/849c26fe-0294-45c3-add7-68eff9abcf57","doi":null,"is_oa":false,"landing_page_url":"https://research.manchester.ac.uk/en/publications/849c26fe-0294-45c3-add7-68eff9abcf57","pdf_url":null,"source":{"id":"https://openalex.org/S4306400662","display_name":"Research Explorer (The University of Manchester)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I28407311","host_organization_name":"University of Manchester","host_organization_lineage":["https://openalex.org/I28407311"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Chetty, M, Mattison, D & Rostami-Hodjegan, A 2012, 'Sex differences in the clearance of CYP3A4 substrates: Exploring possible reasons for the substrate dependency and lack of consensus', Current Drug Metabolism, vol. 13, no. 6, pp. 778-786. https://doi.org/10.2174/138920012800840464","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2073798285","https://openalex.org/W2172119486","https://openalex.org/W4244507579","https://openalex.org/W2013119377","https://openalex.org/W2002353598","https://openalex.org/W2064883756","https://openalex.org/W2086179586","https://openalex.org/W1997538585","https://openalex.org/W1973369172"],"abstract_inverted_index":{"Sex":[0],"differences":[1,66,118,262],"in":[2,25,47,81,111,119,170,172,179,188,210,241,263],"the":[3,53,64,69,75,107,120,165,215,247,252,269],"clearance":[4,121],"of":[5,7,74,87,99,103,110,122,164,205,251,271],"substrates":[6,89],"Cytochrome":[8],"P4503A":[9],"(CYP3A4)":[10],"have":[11,147,255],"been":[12,18],"reported":[13],"frequently":[14],"although":[15],"there":[16],"has":[17],"no":[19],"consensus":[20,272],"on":[21,34,84,273],"reasons":[22],"for":[23,37,155,185,201,218,228],"variation":[24],"observations":[26,42],"amongst":[27],"drugs":[28,104],"which":[29,96,151],"are":[30,97,138,199],"seemingly":[31],"all":[32,48],"dependent":[33],"this":[35,274],"enzyme":[36],"their":[38],"metabolism.":[39],"Moreover,":[40],"these":[41,260],"could":[43],"not":[44],"be":[45,153],"replicated":[46],"studies":[49,113,150,244,254],"even":[50],"when":[51],"investigating":[52],"same":[54],"drugs.":[55],"Differing":[56],"study":[57,77,198],"designs":[58],"and":[59,105,129,146,169,181,226,231,245],"inadequate":[60,256],"power":[61,109,221,257],"to":[62,79,90,115,258,268],"identify":[63],"sex":[65,117,261],"may":[67],"explain":[68],"conflicting":[70],"reports.":[71],"The":[72,235],"aim":[73],"current":[76],"was":[78,177],"use":[80,163],"vitro":[82,171],"data":[83],"a":[85,207,219],"number":[86],"CYP3A4":[88,123],"develop":[91],"mechanistic":[92],"population":[93],"pharmacokinetic":[94],"models":[95],"capable":[98],"integrating":[100],"various":[101],"attributes":[102],"estimating":[106],"statistical":[108],"vivo":[112,173],"designed":[114],"discern":[116],"substrates.":[124,135],"Midazolam,":[125],"triazolam,":[126],"alprazolam,":[127,213],"nifedipine":[128],"zolpidem":[130],"were":[131,222,237],"selected":[132],"as":[133],"test":[134],"These":[136],"compounds":[137],"predominantly":[139],"metabolized":[140],"by":[141,144,162],"CYP3A4,":[142],"unaffected":[143],"p-glycoprotein":[145],"abundant":[148],"clinical":[149,243],"can":[152],"used":[154],"validation":[156],"purposes.":[157],"Simulated":[158],"apparent":[159],"clearance,":[160,265],"obtained":[161],"Simcyp\u00ae":[166],"Population-based":[167],"Simulator":[168],"extrapolation":[174],"(IVIVE)":[175],"techniques,":[176],"compared":[178],"males":[180],"females":[182,211],"after":[183],"correcting":[184],"weight":[186],"(CL/wt)":[187],"1560":[189],"trials.":[190],"Results":[191],"suggested":[192],"that":[193,249],"about":[194,224],"105":[195],"subjects":[196],"per":[197],"required":[200],"an":[202],"80%":[203],"probability":[204],"identifying":[206],"higher":[208],"CL/wt":[209],"with":[212,239],"while":[214],"corresponding":[216],"numbers":[217],"similar":[220],"120,":[223],"150":[225],"300":[227],"nifedipine,":[229],"triazolam":[230],"oral":[232],"midazolam,":[233],"respectively.":[234],"results":[236],"consistent":[238],"outcomes":[240],"published":[242,253],"support":[246],"view":[248],"many":[250],"detect":[259],"drug":[264],"thereby":[266],"contributing":[267],"lack":[270],"subject.":[275]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2126906384","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
